Page last updated: 2024-10-23

aspirin and Precancerous Conditions

aspirin has been researched along with Precancerous Conditions in 43 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Precancerous Conditions: Pathological conditions that tend eventually to become malignant.

Research Excerpts

ExcerptRelevanceReference
"and aims: Aspirin and other non-steroidal anti-inflammatory drugs have been shown to reduce the risk of colorectal cancer (CRC)."7.72Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. ( Bernheim, J; Buklan, G; Freund, HR; Grankin, M; Klein, E; Neufeld, D; Nissan, A; Shpitz, B, 2003)
" We evaluated the effects of aspirin on genetic/epigenetic alterations in precancerous conditions, i."3.85Effects of long-term aspirin use on molecular alterations in precancerous gastric mucosa in patients with and without gastric cancer. ( Das, KM; Fukui, H; Hara, K; Ito, C; Kondo, T; Kono, T; Michigami, Y; Miwa, H; Morimoto, T; Oshima, T; Tomita, T; Tozawa, K; Watari, J; Yamasaki, T, 2017)
"Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects."3.74Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008)
"and aims: Aspirin and other non-steroidal anti-inflammatory drugs have been shown to reduce the risk of colorectal cancer (CRC)."3.72Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. ( Bernheim, J; Buklan, G; Freund, HR; Grankin, M; Klein, E; Neufeld, D; Nissan, A; Shpitz, B, 2003)
"Effects of inhibitors of arachidonic acid (AA) metabolism on the development of fatty liver, cirrhosis, glutathione-S-transferase placental form (GST-P)-positive nodules and the generation of 8-hydroxydeoxyguanosine (8-OHdG) and thiobarbituric acid-reactive substances (TBARS), caused by a choline-deficient, L-amino acid-defined (CDAA) diet, were examined in male Fischer 344 rats by feeding CDAA diets supplemented with the inhibitors for 12 and 30 weeks."3.69Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. ( Denda, A; Endoh, T; Horiguchi, K; Kobayashi, E; Konishi, Y; Nakae, D; Noguchi, O; Ogasawara, H; Sugimura, M; Tamura, K; Tang, Q; Tsujiuchi, T, 1996)
"Barrett's metaplasia is one of the commonest premalignant lesions in the western world following colorectal adenomas."2.47Acid reflux and oesophageal cancer. ( Jankowski, J; Nicholson, A, 2011)
"Colorectal cancer is the second leading cause of mortality in the United States."2.43Colorectal cancer prevention. ( Hawk, ET; Levin, B, 2005)
"In familial and sporadic colorectal cancer, aspirin, other nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors have been tested for their ability to reduce polyp and cancer development in clinical studies."2.42Review article: the chemoprevention of colorectal carcinoma. ( Gasche, C, 2004)
"Barrett esophagus is a premalignant change of the esophagus; however, malignant transformation to esophageal adenocarcinoma is rare in patients without dysplasia."1.72Barrett Esophagus: Rapid Evidence Review. ( Bryce, C; Bucaj, M; Gazda, R, 2022)
"Gallbladder stones (cholecystolithiasis) are the main risk factor for gallbladder cancer (GBC), a lethal biliary malignancy with poor survival rates worldwide."1.56Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia. ( Arrese, M; Bizama, C; Espinoza, JA; Ferreccio, C; García, P; Gómez, N; González, X; Guevara, F; Kalergis, AM; Lobos-González, L; Miquel, JF; Muñoz-Durango, N; Roa, JC; Rosa, L; Saavedra, N; Villegas, J; Wichmann, IA, 2020)
"The risk of gastric cancer (GC) declines after Helicobacter pylori (H."1.51DNA methylation silencing of microRNA gene methylator in the precancerous background mucosa with and without gastric cancer: Analysis of the effects of H. pylori eradication and long-term aspirin use. ( Das, KM; Fukui, H; Ito, C; Miwa, H; Oshima, T; Shimoda, T; Tomita, T; Watari, J, 2019)
"examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib."1.35Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008)
"Aspirin may suppress tumour incidence via salicylate by enhancing apoptosis in carcinogen-initiated cells."1.30Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. ( Barnes, CJ; Cameron, IL; Hardman, WE; Lee, M, 1998)
"The dose-response relationship in male F344 rats was determined for the ability of aspirin administered in the diet to prevent azoxymethane (AOM)-induced colon cancer and aberrant crypt foci (ACF) and to reduce prostaglandin E2 (PGE2) levels."1.30Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. ( Conran, P; Hawk, EE; Kelloff, GJ; Kramer, PM; Li, H; Lubet, RA; Pereira, MA; Schut, HA; Steele, VE, 1999)

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-19902 (4.65)18.7374
1990's10 (23.26)18.2507
2000's14 (32.56)29.6817
2010's13 (30.23)24.3611
2020's4 (9.30)2.80

Authors

AuthorsStudies
Bryce, C1
Bucaj, M1
Gazda, R1
Watari, J2
Ito, C2
Shimoda, T1
Tomita, T2
Oshima, T2
Fukui, H2
Das, KM2
Miwa, H2
Song, Y1
Zhong, X1
Gao, P1
Zhou, C1
Shi, J1
Wu, Z1
Guo, Z1
Wang, Z1
Rosa, L1
Lobos-González, L1
Muñoz-Durango, N1
García, P1
Bizama, C1
Gómez, N1
González, X1
Wichmann, IA1
Saavedra, N1
Guevara, F1
Villegas, J1
Arrese, M1
Ferreccio, C1
Kalergis, AM1
Miquel, JF1
Espinoza, JA1
Roa, JC1
Braillon, A1
Michigami, Y1
Hara, K1
Yamasaki, T1
Kondo, T1
Kono, T1
Tozawa, K1
Morimoto, T1
Christudoss, P2
Chacko, G1
Selvakumar, R2
Fleming, JJ2
Pugazhendhi, S1
Mathew, G2
Pulimood, AB1
Cowie, A1
Noble, F1
Underwood, T1
Falk, GW1
Jankowski, J4
Hur, C1
Broughton, DE1
Ozanne, E1
Yachimski, P1
Nishioka, NS1
Gazelle, GS1
Gatenby, PA1
Ramus, JR1
Caygill, CP1
Winslet, MC1
Watson, A1
Wallace, K1
Grau, MV1
Ahnen, D1
Snover, DC1
Robertson, DJ1
Mahnke, D1
Gui, J1
Barry, EL1
Summers, RW1
McKeown-Eyssen, G1
Haile, RW1
Baron, JA1
Wang, AY1
Emura, F1
Oda, I1
Cox, DG1
Kim, HS1
Yeaton, P1
Jankowski, JA1
Hooper, PA1
Wang, F1
Lv, ZS1
Fu, YK1
Gravitz, L1
Nicholson, A1
Chaudhary, A1
Sutaria, D1
Huang, Y1
Wang, J1
Prabhu, S1
Femia, AP1
Salvianti, F1
Luceri, C1
Dolara, P1
Salvadori, M1
Pinzani, P1
Caderni, G1
Hull, M1
Logan, RF1
Mølck, AM1
Poulsen, M1
Meyer, O1
Hawk, ET2
Viner, JL1
Shpitz, B1
Klein, E1
Buklan, G1
Neufeld, D1
Nissan, A1
Freund, HR1
Grankin, M1
Bernheim, J1
Gasche, C1
Raj, A1
Levin, B1
Stark, LA1
Reid, K1
Sansom, OJ1
Din, FV1
Guichard, S1
Mayer, I1
Jodrell, DI1
Clarke, AR1
Dunlop, MG1
Moral, MA1
Khurdayan, VK1
Bozzo, J1
Leedham, S1
Ye, B1
Zhang, YX1
Yang, F1
Chen, HL1
Xia, D1
Liu, MQ1
Lai, BT1
Wargovich, MJ1
Chen, CD1
Harris, C1
Yang, E1
Velasco, M1
Morgan, GP1
Mereto, E1
Frencia, L1
Ghia, M1
Tang, Q2
Denda, A2
Tsujiuchi, T2
Tsutsumi, M1
Amanuma, T1
Murata, Y1
Maruyama, H1
Konishi, Y2
Endoh, T1
Noguchi, O1
Kobayashi, E1
Tamura, K1
Horiguchi, K1
Ogasawara, H1
Nakae, D1
Sugimura, M1
Schatzkin, A1
Lanza, E1
Freedman, LS1
Tangrea, J1
Cooper, MR1
Marshall, JR1
Murphy, PA1
Selby, JV1
Shike, M1
Schade, RR1
Burt, RW1
Kikendall, JW1
Cahill, J1
Barnes, CJ1
Cameron, IL1
Hardman, WE1
Lee, M1
Morgan, G1
Seidensticker, F1
Schmiegel, WH1
Li, H1
Schut, HA1
Conran, P1
Kramer, PM1
Lubet, RA1
Steele, VE1
Hawk, EE1
Kelloff, GJ1
Pereira, MA1
Laugier, P1
Olmos, L1
Steppert, A1
Wruhs, O1
Zandanell, E1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Role of in Vivo Real Time Endocytoscopy in Diagnosing Colorectal Neoplasia[NCT02324374]50 participants (Actual)Interventional2011-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

10 reviews available for aspirin and Precancerous Conditions

ArticleYear
Aspirin and Its Potential Preventive Role in Cancer: An Umbrella Review.
    Frontiers in endocrinology, 2020, Volume: 11

    Topics: Aspirin; Chemoprevention; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Meta-Ana

2020
Strategies to improve outcomes in esophageal adenocarcinoma.
    Expert review of anticancer therapy, 2014, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; Barrett Esophagus; Combined Modality Therapy; Cytodi

2014
Chemoprevention in Barrett's esophagus: A pill a day?
    Gastrointestinal endoscopy clinics of North America, 2011, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Diet; Esophagea

2011
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2011, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Control St

2011
Acid reflux and oesophageal cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 185

    Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cyclooxygenase 2; Esophageal Neoplasms; Esophagitis; Gas

2011
Review article: the chemoprevention of colorectal carcinoma.
    Alimentary pharmacology & therapeutics, 2004, Volume: 20 Suppl 4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Chemoprevention; Chromosoma

2004
Acid suppression and chemoprevention in Barrett's oesophagus.
    Digestive diseases (Basel, Switzerland), 2004, Volume: 22, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Enzyme Inhib

2004
Colorectal cancer prevention.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-10, Volume: 23, Issue:2

    Topics: Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Colo

2005
Chronicles in drug discovery.
    Drug news & perspectives, 2006, Volume: 19, Issue:8

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Budesonide; Cell

2006
[Practice-relevant intestinal diseases: prevention of colon carcinoma].
    Praxis, 1998, Nov-26, Volume: 87, Issue:48

    Topics: Adenomatous Polyposis Coli; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyp

1998

Trials

2 trials available for aspirin and Precancerous Conditions

ArticleYear
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2009, Volume: 18, Issue:5

    Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cohort Studies; Demography; Eso

2009
The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1996, Volume: 5, Issue:5

    Topics: Adenoma; Adenomatous Polyps; Adult; Aspirin; Colonic Neoplasms; Colonic Polyps; Colonoscopy; Demogra

1996

Other Studies

31 other studies available for aspirin and Precancerous Conditions

ArticleYear
Barrett Esophagus: Rapid Evidence Review.
    American family physician, 2022, Volume: 106, Issue:4

    Topics: Adenocarcinoma; Anti-Inflammatory Agents; Aspirin; Barrett Esophagus; Esophageal Neoplasms; Humans;

2022
DNA methylation silencing of microRNA gene methylator in the precancerous background mucosa with and without gastric cancer: Analysis of the effects of H. pylori eradication and long-term aspirin use.
    Scientific reports, 2019, 08-29, Volume: 9, Issue:1

    Topics: Aged; Aspirin; Cohort Studies; DNA Methylation; Female; Gastric Mucosa; Gene Silencing; Helicobacter

2019
Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia.
    Molecular oncology, 2020, Volume: 14, Issue:11

    Topics: Animals; Aspirin; Chemoprevention; Cholecystolithiasis; Cholesterol; Cholesterol, Dietary; Chronic D

2020
RE: Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial.
    JNCI cancer spectrum, 2021, Volume: 5, Issue:1

    Topics: Aspirin; Humans; Lung; Lung Neoplasms; Multiple Pulmonary Nodules; Precancerous Conditions

2021
Effects of long-term aspirin use on molecular alterations in precancerous gastric mucosa in patients with and without gastric cancer.
    Scientific reports, 2017, 10-17, Volume: 7, Issue:1

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; CpG

2017
Expression of Metallothionein after Administration of Aspirin, Vitamin C or Zinc Supplement in the DMH Induced Colon Carcinoma in Rat
    Asian Pacific journal of cancer prevention : APJCP, 2018, Nov-29, Volume: 19, Issue:11

    Topics: 1,2-Dimethylhydrazine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Aspirin; Col

2018
Protective role of aspirin, vitamin C, and zinc and their effects on zinc status in the DMH-induced colon carcinoma model.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:8

    Topics: 1,2-Dimethylhydrazine; Alkaline Phosphatase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antio

2013
Chemoprevention and Barrett's esophagus: decisions, decisions.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:10

    Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc

2008
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:10

    Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc

2008
The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2009, Volume: 18, Issue:8

    Topics: Age Factors; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Body

2009
Endoscopic submucosal dissection with electrosurgical knives in a patient on aspirin therapy (with video).
    Gastrointestinal endoscopy, 2010, Volume: 72, Issue:5

    Topics: Aged; Aspirin; Dissection; Electrosurgery; Female; Gastric Mucosa; Humans; Platelet Aggregation Inhi

2010
Chemoprevention: First line of defence.
    Nature, 2011, Mar-24, Volume: 471, Issue:7339

    Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I

2011
Chemoprevention of colon cancer in a rat carcinogenesis model using a novel nanotechnology-based combined treatment system.
    Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:10

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; As

2011
Sustained proliferation and resistance to apoptosis after a cytotoxic insult are early alterations in rat colon carcinogenesis.
    International journal of cancer, 2012, Aug-01, Volume: 131, Issue:3

    Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; Aspirin; bcl-2 Homologous Antagonist-Killer Protein; Biom

2012
Chemoprevention in gastroenterology.
    Best practice & research. Clinical gastroenterology, 2011, Volume: 25, Issue:4-5

    Topics: Anticarcinogenic Agents; Aspirin; Chemoprevention; Cyclooxygenase 2 Inhibitors; Digestive System Neo

2011
The combination of 1alpha,25(OH2)-vitamin D3, calcium and acetylsalicylic acid affects azoxymethane-induced aberrant crypt foci and colorectal tumours in rats.
    Cancer letters, 2002, Dec-01, Volume: 186, Issue:1

    Topics: Animals; Aspirin; Azoxymethane; Body Weight; Calcitriol; Calcium; Colorectal Neoplasms; Dose-Respons

2002
Aspirin: still learning about the wonder drug.
    Gut, 2003, Volume: 52, Issue:11

    Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neopl

2003
Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer.
    Gut, 2003, Volume: 52, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; As

2003
Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer.
    Carcinogenesis, 2007, Volume: 28, Issue:5

    Topics: Animals; Apoptosis; Aspirin; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationshi

2007
The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus--the good, the bad, and the flawed!
    The American journal of gastroenterology, 2007, Volume: 102, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Chemoprevent

2007
Induction of lung lesions in Wistar rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by aspirin and phenethyl isothiocyanate.
    BMC cancer, 2007, May-29, Volume: 7

    Topics: Animals; Anticarcinogenic Agents; Aspirin; Carcinogens; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor

2007
Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon.
    International journal of cancer, 1995, Feb-08, Volume: 60, Issue:4

    Topics: Acetaminophen; Adenoma; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti

1995
NSAIDs and the chemoprevention of colon and oesophageal cancer.
    Gut, 1995, Volume: 36, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Esophageal Neoplasms; Humans; P

1995
Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine.
    Cancer letters, 1994, Jan-15, Volume: 76, Issue:1

    Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Aspirin; Body Weight; Carcinogens; Cell Div

1994
Inhibitory effects of inhibitors of arachidonic acid metabolism on the evolution of rat liver preneoplastic foci into nodules and hepatocellular carcinomas with or without phenobarbital exposure.
    Japanese journal of cancer research : Gann, 1993, Volume: 84, Issue:2

    Topics: Acetophenones; Animals; Arachidonic Acid; Aspirin; Cyclooxygenase Inhibitors; Diethylnitrosamine; Li

1993
Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats.
    Carcinogenesis, 1996, Volume: 17, Issue:3

    Topics: Acetophenones; Animals; Aspirin; Choline; Choline Deficiency; Cyclooxygenase Inhibitors; Fatty Liver

1996
Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis.
    British journal of cancer, 1998, Volume: 77, Issue:4

    Topics: 1,2-Dimethylhydrazine; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apopt

1998
Correspondence re: R. Kim et al., Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol., Biomark. Prev., 6: 369-377, 1997.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1998, Volume: 7, Issue:3

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cell Transforma

1998
Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon.
    Carcinogenesis, 1999, Volume: 20, Issue:3

    Topics: Animals; Aspirin; Azoxymethane; Colon; Colonic Neoplasms; Dinoprostone; Dose-Response Relationship,

1999
[Drug induced pseudolymphoma].
    Zeitschrift fur Hautkrankheiten, 1978, May-15, Volume: 53, Issue:10

    Topics: Adult; Aged; Aspirin; Diagnosis, Differential; Female; Humans; Keratosis; Lymphoma; Male; Precancero

1978
[Sclerosing and atrophic lichen of the penis].
    Munchener medizinische Wochenschrift (1950), 1970, Jul-17, Volume: 29

    Topics: Adrenal Cortex Hormones; Adult; Aspirin; Atrophy; Balanitis; Chloroquine; Circumcision, Male; Humans

1970